Vanquish Bio LLC

Longwood, FL · Biotech · Private

NK cell-derived extracellular vesicles (EVs) for targeted destruction of myeloma tumor cells

vanqbio.com →
Grants
$400K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer$399,580
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1958PAXVAX, INC.—$58M
1959Synbiotic Health, Inc.—$6.0M
1960CelLink Corp—$25M
1961Vanquish Bio LLC——
1962Humanity Inc.—$2.4M
1963Verastem Oncology——
1964VIRONGY BIOSCIENCES, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.